Modern medicine has become extraordinarily powerful, but the experience of receiving it still depends on a surprisingly old set of assumptions. Many of the most important therapies in the world are delivered through needles, refrigeration, sharps disposal, and routines that ask patients to organize part of their lives around treatment. That burden shapes adherence, access, cost, and who can realistically benefit from the therapies science has already made possible. As more medicines move toward complex biologics and chronic use, the need is not just for better drugs, but for a fundamentally better way to deliver them.
Terrestrial Bio is building that better way. Using the skin as a delivery pathway, the company has developed a temperature-stable microarray patch (MAP) platform that can administer a wide range of biologics without needles, without refrigeration, and with a wear time of just five minutes. The idea is straightforward, but the implication is significant: if powerful therapies can be delivered in a format that patients prefer and systems can support more easily, then access expands not only because a treatment exists, but because it finally fits how people live. In preclinical models, the company’s lead patch has demonstrated bioavailability greater than 80%, pharmacokinetics comparable to subcutaneous injection, and, in human factors testing, >95% of participants preferred the patch to a needle.
What makes that difficult is not designing something patch-like. Rather, it is achieving reliable delivery of clinically meaningful amounts of medicines in a format that is stable, consistent, manufacturable, and simple enough for real-world use. Terrestrial Bio's MAP platform is built around a specific architectural choice: deployable bioactive tips that separate from the patch base upon application and remain embedded in the skin, dissolving and releasing the drug after the patch is removed. That design gives the company precise control over the amount or dose of medicine delivered while preserving the simplicity of a self-administered product. It is a fundamental departure from conventional dissolving microneedles, which embed the drug throughout the needle structure and have struggled with inconsistent amounts of medicine delivered into the body and low availability of the medicine where it is needed. In formal preclinical studies using minipigs, Terrestrial Bio’s patch delivered 83% to 93% percent of its loaded dose and achieved a half-life comparable to auto-injections; a combination of consistency, efficiency, and clinical-dose capacity that no other patch-based approach has demonstrated.
Terrestrial Bio’s lead program makes the opportunity concrete. The company is developing a once-weekly semaglutide patch for obesity and metabolic disease, an area where patient demand is enormous, and delivery friction is obvious. GLP-1 therapies have shown tremendous health benefits, but they have also made clear how much format still matters. Global GLP-1 sales exceeded $50 billion in 2024, yet only a small fraction of eligible patients have meaningfully used these therapies, with roughly half discontinuing use due to cost, access, tolerability, and injection burden. Because semaglutide already has an extensive record of safety and efficacy data, Terrestrial Bio is able to pursue a 505(b)(2) regulatory pathway– one that focuses the company’s clinical program on demonstrating that the patch delivers the drug comparably and safely, rather than repeating the large-scale trials already completed for the injectable form. The company aims to initiate Phase 1 later this year, with initial clinical data expected by year-end. Beyond prescription approval, the company is pursuing an Rx-to-OTC switch that would make low-dose semaglutide available without a prescription for weight maintenance and prevention—a potential first in the GLP-1 category.
The team behind Terrestrial Bio brings credibility rooted in the specific constraints of this problem. CEO Rachel Sha spent seventeen years at Genzyme and Sanofi, leading business development and commercial transactions across modalities before joining Engine Ventures as an Operating Partner. Chief Science Officer Kathryn Kosuda has led the platform’s research for over a decade, attracting funding from federal agencies and NGO’s. Chief Development Officer Lynda Tussey has taken multiple programs into clinical development at Merck and GSK. VP of Manufacturing Raymond Knox brings twenty-five years of experience advancing drug-delivery products from bench to commercial scale. Their conviction comes from a practical observation: the GLP-1 market is not constrained by the drug itself, but by how it reaches patients.
Beyond GLP-1s, the larger story is platform breadth. Terrestrial Bio's MAP platform is designed to support peptides, proteins, vaccines, and combination products; a flexibility that has already attracted partnerships with several global biopharma companies. The company has built a clinical-grade manufacturing facility in Woburn, Massachusetts, and is transitioning from pilot-scale production to a continuous automated line capable of producing millions of units annually in a new R&D/manufacturing facility in Boston. At commercial scale, the cost of patch delivery is anticipated to be more favorable than that of autoinjectors, an economic advantage that becomes more consequential as pricing pressure intensifies across the biologics landscape.
When Terrestrial Bio succeeds, the impact will extend well beyond a better patch. Some of the most powerful medicines in the world will no longer be tied so tightly to needles, cold-chain logistics, and clinical infrastructure. They will be easier to use, easier to move, and easier to bring to more people; not merely approved, but deliverable without friction; not merely effective, but practical in the context of life. That is an ambitious goal. It is also a pragmatic one.
